GHENT, Belgium, Oct. 29, 2013 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels:ABLX] today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer's disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx. The Phase I study involves a single-centre, partially randomised, single-blind, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of intravenous and subcutaneous injections with the Nanobody in healthy subjects. The trial is expected to recruit 80 healthy volunteers and results are anticipated during H2 2014. Dr Edwin Moses, Chairman and CEO of Ablynx commented: "We are very pleased that Boehringer Ingelheim has dosed the first healthy volunteers as part of our collaboration in Alzheimer's disease which we started in 2007. The Nanobody's progress into the clinic demonstrates their belief in its potential as a valuable treatment option for patients suffering from this complex disease for which no adequate drugs are currently available. It is the second of Ablynx's partnered programmes that has entered clinical development this year and further enhances our pipeline which now contains seven Nanobody products at clinical development stage." In January 2007, Boehringer Ingelheim and Ablynx announced a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies against a single disease target. The collaboration has a potential value of $265 million in upfront and milestone payments plus undisclosed royalties on product sales. Boehringer Ingelheim is solely responsible for the development, manufacturing and commercialisation of any products resulting from the collaboration. About Alzheimer's disease Alzheimer's disease is a neurodegenerative disease of the brain which leads to loss of memory and cognitive functions. It is the most common form of dementia in adults. It is estimated that 35.6 million people worldwide were living with dementia in 2010. With the global population aging, this number is expected to triple by 2050. Marketed products address some of the symptoms of the disease but there remains a high unmet medical need as there are currently no treatments available that delay or halt the progression of the disease.
About AblynxAblynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has on-going research collaborations and significant partnerships with major pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com .
|For more information, please contact|
|Dr Edwin Moses|
|Chairman and CEO|
|t: +32 (0)9 262 00 07|
|m: +44 (0)7771 954 193 /|
|+32 (0)473 39 50 68|
|Associate Director Investor Relations|
|t: +32 (0)9 262 00 82|
|m: +32 (0)479 49 06 03|
|Follow us on Twitter @AblynxABLX|
|Ablynx media relations Consilium Strategic Communications:|
|Mary-Jane Elliott, Amber Bielecka, Lindsey Neville|
|t: +44 207 920 2345|